These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1899311)

  • 1. Deletion of graft reactive cells by idarubicin-anti-CD8 (Ly-2.1) immunoconjugate: studies in the mouse heart graft model.
    Mottram PL; Pietersz GA; Purcell LJ; Krauer K; Clunie GJ; McKenzie IF
    Transplant Proc; 1991 Feb; 23(1 Pt 1):499-500. PubMed ID: 1899311
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunosuppression by anti-CD8 (Ly-2.1) MAb conjugated to idarubicin: studies in the mouse heart graft model.
    Mottram PL; Pietersz GA; Purcell LJ; Clunie GJ; McKenzie IF
    Transplant Proc; 1990 Oct; 22(5):2111-2. PubMed ID: 2120812
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-T cell-specific immunoconjugates in mice: in vivo effects.
    Mottram PL; Smyth M; Pietersz GA; Clunie GJ; McKenzie IF
    Transplant Proc; 1989 Oct; 21(5):3757-8. PubMed ID: 2573184
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolerance induction with anti-CD8 monoclonal antibodies in the mouse heart transplant model.
    Mottram PL; Purcell LJ; Pietersz GA; McKenzie IF
    Transplant Proc; 1993 Oct; 25(5):2935-6. PubMed ID: 8212289
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunosuppression by aminopterin or idarubicin conjugated to anti-CD8 in the mouse heart allograft model.
    Mottram PL; Pietersz GA; Purcell LJ; Krauer K; McKenzie IF
    Transplant Proc; 1992 Oct; 24(5):2301. PubMed ID: 1413068
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence that an anthracycline-anti-CD8 immunoconjugate, idarubicin-anti-Ly-2.1, prolongs heart allograft survival in mice.
    Mottram PL; Pietersz GA; Smyth MJ; Purcell LJ; Clunie GJ; McKenzie IF
    Transplantation; 1993 Mar; 55(3):484-90. PubMed ID: 8456465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between CD4 and CD8 T cells determines graft outcome in monoclonal antibody-treated mice.
    Hamano K; Morris PJ; Wood KJ
    Transplant Proc; 1993 Feb; 25(1 Pt 1):792-3. PubMed ID: 8438483
    [No Abstract]   [Full Text] [Related]  

  • 8. Distribution of Ly-6C on lymphocyte subsets: I. Influence of allotype on T lymphocyte expression.
    Schlueter AJ; Malek TR; Hostetler CN; Smith PA; deVries P; Waldschmidt TJ
    J Immunol; 1997 May; 158(9):4211-22. PubMed ID: 9126982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation and regeneration of a novel anti-CD8-resistant cytolytic T lymphocyte population.
    Dougall DS; Lamousé-Smith ES; McCarthy SA
    Cell Immunol; 2000 Oct; 205(1):1-12. PubMed ID: 11078602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of anti-L3T4 and anti-LYT2 monoclonal antibody therapy on cardiac allograft survival in presensitized recipients.
    Madsen JC; Wood KJ; Morris PJ
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1022. PubMed ID: 2495588
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful islet allografting requires depletion of both Lyt-2+ and L3T4+ cells.
    Yamamoto H; Monden M; Gotoh M; Ichikawa T; Kubota N; Kawai M; Mori T; Sakurai M; Uenaka A; Nakayama E
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2707-8. PubMed ID: 2495676
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-CD4 IgG2a monoclonal antibody treatment prevents the expansion of T cells in the spleen during murine graft-vs-host disease.
    Noort WA; Benner R; Savelkoul HF
    Transplant Proc; 1995 Feb; 27(1):384-6. PubMed ID: 7879030
    [No Abstract]   [Full Text] [Related]  

  • 13. The synergistic effect of anti-CD4 monoclonal antibodies and cyclosporin A on murine fetal islet allograft survival.
    Burkhardt K; Charlton B; Mandel TE
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2663-4. PubMed ID: 2495663
    [No Abstract]   [Full Text] [Related]  

  • 14. Antitumor activity of idarubicin-monoclonal antibody conjugates in a disseminated thymic lymphoma model.
    Smyth MJ; Bogdanovski M; McKenzie IF; Pietersz GA
    Cancer Res; 1991 Jan; 51(1):310-7. PubMed ID: 1988093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of murine lupus with monoclonal antibody to L3T4. II. Effects on immunohistopathology of thymus, spleen, and lymph node.
    Ermak TH; Steger HJ; Wofsy D
    Lab Invest; 1989 Oct; 61(4):447-56. PubMed ID: 2529396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine cardiac allograft survival following treatment of recipients with monoclonal anti-L3T4 or Ly-2 antibodies.
    Mottram PL; Wheelahan J; McKenzie IF; Clunie GJ
    Transplant Proc; 1987 Apr; 19(2):2898-901. PubMed ID: 3105127
    [No Abstract]   [Full Text] [Related]  

  • 18. Cyclophosphamide-induced tolerance in fully allogeneic heart transplantation in mice.
    Matsuura A; Katsuno M; Suzuki Y; Ito T; Yasuura K; Abe T; Yoshikai Y
    Cell Immunol; 1994 May; 155(2):501-7. PubMed ID: 8181080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppression of graft rejection with idarubicin-monoclonal antibody conjugates by elimination of T cell subsets in vivo.
    Smyth MJ; Pietersz GA; McKenzie IF
    Transplantation; 1988 Jul; 46(1):126-31. PubMed ID: 2899362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of L3T4 and Lyt-2 monoclonal antibodies on islet xenograft (rat to mouse) rejection.
    Kawai M; Gotoh M; Monden M; Yamamoto H; Ichikawa T; Valdivia LA; Mori T; Uenaka A; Nakayama E
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2709-10. PubMed ID: 2495677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.